102 lines
32 KiB
Text
102 lines
32 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK604944">
|
|
<meta name="ncbi_domain" content="nciprotocols">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK604944/?report=reader">
|
|
<meta name="ncbi_pagename" content="Detection of Mycoplasma Contamination in Nanoparticle Formulations - National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Detection of Mycoplasma Contamination in Nanoparticle Formulations - National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/nciprotocols/ncipr83/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/nciprotocols/ncipr72/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/nciprotocols/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]">
|
|
<meta name="citation_title" content="Detection of Mycoplasma Contamination in Nanoparticle Formulations">
|
|
<meta name="citation_publisher" content="National Cancer Institute (US)">
|
|
<meta name="citation_date" content="2020/09">
|
|
<meta name="citation_author" content="Timothy M. Potter">
|
|
<meta name="citation_author" content="Barry W. Neun">
|
|
<meta name="citation_author" content="Marina A. Dobrovolskaia">
|
|
<meta name="citation_pmid" content="39012980">
|
|
<meta name="citation_doi" content="10.17917/PHFP-8573">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK604944/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Detection of Mycoplasma Contamination in Nanoparticle Formulations">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Cancer Institute (US)">
|
|
<meta name="DC.Contributor" content="Timothy M. Potter">
|
|
<meta name="DC.Contributor" content="Barry W. Neun">
|
|
<meta name="DC.Contributor" content="Marina A. Dobrovolskaia">
|
|
<meta name="DC.Date" content="2020/09">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK604944/">
|
|
<meta name="description" content="Mycoplasma is a microorganism that lacks a nucleus and a cell wall which makes it unaffected by many antibiotics. Nanoparticles submitted to the NCL may be subjected to testing for mycoplasma when deemed necessary. The types of nanoparticle formulations generally tested for mycoplasma contamination include those that incorporate a component derived from an animal or hybridoma cultures.">
|
|
<meta name="og:title" content="Detection of Mycoplasma Contamination in Nanoparticle Formulations">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Mycoplasma is a microorganism that lacks a nucleus and a cell wall which makes it unaffected by many antibiotics. Nanoparticles submitted to the NCL may be subjected to testing for mycoplasma when deemed necessary. The types of nanoparticle formulations generally tested for mycoplasma contamination include those that incorporate a component derived from an animal or hybridoma cultures.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK604944/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-nciprotocols-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/nciprotocols/ncipr73/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK604944/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8E71C57C8EBB71000000000094007C.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK604944/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/nciprotocols/ncipr83/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">NCL Method STE-3, Detection of Mycoplasma Contamination in Nanoparticle Formulations: Version 3</div><div class="j">National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]</div></div><div class="tail"><a href="/books/n/nciprotocols/ncipr72/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK604944/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK604944/&text=Detection%20of%20Mycoplasma%20Contamination%20in%20Nanoparticle%20Formulations"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/nciprotocols/?report=reader">Title Information</a><a href="/books/n/nciprotocols/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK604944/?report=classic">Switch to classic view</a><a href="/books/NBK604944/pdf/Bookshelf_NBK604944.pdf">PDF (278K)</a><a href="/books/NBK604944/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK604944%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8E71C57C8EBB71000000000094007C.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK604944_"><span class="label">NCL Method STE-3</span><span class="title" itemprop="name">Detection of Mycoplasma Contamination in Nanoparticle Formulations</span></h1><div class="subtitle whole_rhythm">Version 3</div><p class="contribs">Potter TM, Neun BW, Dobrovolskaia MA.</p><p class="fm-aai"><a href="#_NBK604944_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="ncipr73.s1"><h2 id="_ncipr73_s1_">1. Introduction</h2><p>Mycoplasma is a microorganism that lacks a nucleus and a cell wall which makes it unaffected by many antibiotics. Nanoparticles submitted to the NCL may be subjected to testing for mycoplasma when deemed necessary. The types of nanoparticle formulations generally tested for mycoplasma contamination include those that incorporate a component derived from an animal or hybridoma cultures.</p></div><div id="ncipr73.s2"><h2 id="_ncipr73_s2_">2. Principle</h2><p>The NCL does not perform mycoplasma testing in our laboratory. Rather, this test is outsourced to another department of the Frederick National Laboratory for Cancer Research, the Protein Expression Laboratory (PEL), part of the Cancer Research Technology Program (<a href="https://frederick.cancer.gov/science/Pel/Protocols.aspx" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://frederick.cancer.gov/science/Pel/Protocols.aspx</a>).</p><p>Briefly, the NCL cultures nanoparticles with cells for the initial 24 hours, then passage these cells twenty-five (25) times. The supernatants from the final culture will then be transported to the PEL for mycoplasma testing via VenorGem Mycoplasma PCR-based Detection Kit from Minerva Biolabs, which is also available through Sigma at the link below: <a href="http://www.sigmaaldrich.com/catalog/product/sigma/mp0025?lang=en&region=US" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">http://www.sigmaaldrich.com/catalog/product/sigma/mp0025?lang=en&region=US</a>.</p><p>For more details on the mycoplasma detection protocol, please contact the PEL (<a href="https://frederick.cancer.gov/science/Pel/Protocols.aspx" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://frederick.cancer.gov/science/Pel/Protocols.aspx</a>).</p></div><div id="ncipr73.s3"><h2 id="_ncipr73_s3_">3. Preparation of study samples</h2><p>The assay requires 2.2 mL of the test nanomaterial final formulation. The concentration of nanoparticles in this formulation is case-specific. When such information is not available, for example when a test nanomaterial is received from a commercial supplier in a form not intended for biomedical applications, prepare stock solution at a concentration of 1mg/mL. The weight information can refer to either active pharmaceutical ingredient or total construct; it can also represent total metal content or other units. Such information is specific to each nanoparticle and should be recorded to aid result interpretation. Test nanoparticles should be reconstituted in sterile PBS, water or in appropriate vehicle. If vehicle is a buffer or media other than water or PBS, the vehicle control should be included in the test. The samples are tested from stock. However, when nanoparticles carry cytotoxic drugs or are otherwise toxic to cells, select the highest non-toxic concentration. The pH of the study sample should be checked using a pH microelectrode and adjusted with either sterile NaOH or HCl as necessary to be within the pH range 6-8. If NaOH or HCl are not compatible with a given nanoparticle formulation, adjust pH using a procedure recommended by nanomaterial manufacturer. To avoid sample contamination from microelectrode, always remove a small aliquot of the sample for use in measuring the pH.</p></div><div id="ncipr73.s4"><h2 id="_ncipr73_s4_">4. Reagents and Equipment</h2><blockquote><p><i>Note: The NCL does not endorse any of the suppliers listed below; these reagents were used in the development of the protocol and their inclusion is for informational purposes only. Equivalent supplies from alternate vendors can be substituted. Please note that suppliers may undergo a name change due to a variety of factors. Brands and part numbers typically remain consistent but may also change over time</i>.</p></blockquote><dl id="ncipr73.l1" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>4.1.</dt><dd id="ncipr73.lt1"><p class="no_top_margin">Reagents
|
|
<dl id="ncipr73.l2" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>4.1.1.</dt><dd id="ncipr73.lt2"><p class="no_top_margin">Phosphate buffered saline (PBS) (GE Life Sciences, SH30256.01)</p></dd></dl><dl class="bkr_refwrap"><dt>4.1.2.</dt><dd id="ncipr73.lt3"><p class="no_top_margin">Fetal bovine serum (FBS) (GE Life Sciences, Hyclone, SH30070.03)</p></dd></dl><dl class="bkr_refwrap"><dt>4.1.3.</dt><dd id="ncipr73.lt4"><p class="no_top_margin">Penicillin streptomycin solution (GE Life Sciences, Hyclone, SV30010)</p></dd></dl><dl class="bkr_refwrap"><dt>4.1.4.</dt><dd id="ncipr73.lt5"><p class="no_top_margin">Trypan Blue solution (Gibco, 15250-061)</p></dd></dl><dl class="bkr_refwrap"><dt>4.1.5.</dt><dd id="ncipr73.lt6"><p class="no_top_margin">RPMI-1640 (GE Life Sciences, HyClone, SH30096.01)</p></dd></dl></dl></p></dd></dl><dl class="bkr_refwrap"><dt>4.2.</dt><dd id="ncipr73.lt7"><p class="no_top_margin">Equipment and Materials
|
|
<dl id="ncipr73.l3" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>4.2.1.</dt><dd id="ncipr73.lt8"><p class="no_top_margin">Pipettes, 0.05 to 10 mL</p></dd></dl><dl class="bkr_refwrap"><dt>4.2.2.</dt><dd id="ncipr73.lt9"><p class="no_top_margin">Polypropylene tubes, 50 and 15 mL</p></dd></dl><dl class="bkr_refwrap"><dt>4.2.3.</dt><dd id="ncipr73.lt10"><p class="no_top_margin">T25 culture flasks</p></dd></dl><dl class="bkr_refwrap"><dt>4.2.4.</dt><dd id="ncipr73.lt11"><p class="no_top_margin">Centrifuge</p></dd></dl><dl class="bkr_refwrap"><dt>4.2.5.</dt><dd id="ncipr73.lt12"><p class="no_top_margin">Refrigerator, 2-8°C</p></dd></dl><dl class="bkr_refwrap"><dt>4.2.6.</dt><dd id="ncipr73.lt13"><p class="no_top_margin">Freezer, −20°C</p></dd></dl><dl class="bkr_refwrap"><dt>4.2.7.</dt><dd id="ncipr73.lt14"><p class="no_top_margin">Cell culture incubator, 5% CO<sub>2</sub> and 95% humidity.</p></dd></dl><dl class="bkr_refwrap"><dt>4.2.8.</dt><dd id="ncipr73.lt15"><p class="no_top_margin">Biohazard safety cabinet approved for level II handling of biological material</p></dd></dl><dl class="bkr_refwrap"><dt>4.2.10.</dt><dd id="ncipr73.lt16"><p class="no_top_margin">Inverted microscope</p></dd></dl><dl class="bkr_refwrap"><dt>4.2.10.</dt><dd id="ncipr73.lt17"><p class="no_top_margin">Vortex</p></dd></dl><dl class="bkr_refwrap"><dt>4.2.11.</dt><dd id="ncipr73.lt18"><p class="no_top_margin">Hemocytometer</p></dd></dl></dl></p></dd></dl></dl></div><div id="ncipr73.s5"><h2 id="_ncipr73_s5_">5. Preparation of cells for mycoplasma testing</h2><dl id="ncipr73.l4" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>5.1.</dt><dd id="ncipr73.lt19"><p class="no_top_margin">Identify a quickly proliferating cell line (e.g. NCI H460) and grow it in the complete culture media appropriate for this cell line.</p></dd></dl><dl class="bkr_refwrap"><dt>5.2.</dt><dd id="ncipr73.lt20"><p class="no_top_margin">Add 1mL of test nanoparticle formulation and negative control to the cell culture media. Use 10 mL of culture media per flask. Test each sample in duplicate.</p></dd></dl><dl class="bkr_refwrap"><dt>5.3.</dt><dd id="ncipr73.lt21"><p class="no_top_margin">Incubate cells for 24 hours, then replace growth medium with 5 mL of fresh complete medium appropriate for your cell line.</p></dd></dl><dl class="bkr_refwrap"><dt>5.4.</dt><dd id="ncipr73.lt22"><p class="no_top_margin">Split cells as needed and passage 25 times. Use 5 mL of culture media for all passages after initial treatment. Some detection methods may require the use of antibiotic free media. Mycoplasma is typically resistant to common cell culture antibiotics; however, the presence of antibiotics can produce erroneous results in certain tests. Consult your testing method for guidance.</p></dd></dl><dl class="bkr_refwrap"><dt>5.5.</dt><dd id="ncipr73.lt23"><p class="no_top_margin">After last passage, collect supernatants for mycoplasma detection by appropriate method (PCR or ELISA).</p></dd></dl></dl><p><b>Note</b>: This method is not intended to certify the nanoformulation as mycoplasma free. It is used to ensure that no mycoplasma is introduced into cell culture and transmitted to <i>in vitro</i> or <i>in vivo</i> (in case of xenograft studies) assays.</p></div><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_top_margin"><p>This protocol assumes an intermediate level of scientific competency with regard to techniques, instrumentation, and safety procedures. Rudimentary assay details have been omitted for the sake of brevity.</p></p></div></dd></dl><dl class="bkr_refwrap"><dt>*</dt><dd><div id="ncipr73.fn1"><p class="no_top_margin">address correspondence to: <a href="mailto:dev@null" data-email="vog.hin.liam@aniram" class="oemail">vog.hin.liam@aniram</a></p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_top_margin"><div>
|
|
<span class="mixed-citation" id="ncipr73.suggestedcitation">Potter TM, Neun BW, Dobrovolskaia MA, NCL Method STE-3: Detection of Mycoplasma Contamination in Nanoparticle Formulations. <a href="https://ncl.cancer.gov/resources/assay-cascade-protocols" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://ncl.cancer.gov/resources/assay-cascade-protocols</a> DOI: <a href="http://dx.crossref.org/10.17917/PHFP-8573" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">10.17917/PHFP-8573</a></span>
|
|
</div></p></div></dd></dl></dl></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK604944_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><p class="contrib-group"><h4>Authors</h4><span itemprop="author">Timothy M. Potter</span>, <span itemprop="author">Barry W. Neun</span>, and <span itemprop="author">Marina A. Dobrovolskaia</span><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup>1</sup>.</p><h4>Contact</h4><div class="affiliation"><sup>1</sup> <span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.liam@aniram" class="oemail">vog.hin.liam@aniram</a></div><div class="affiliation"><sup>1</sup> Nanotechnology Characterization Lab, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD 21702</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div><h3>Publication History</h3><p class="small">Published: <span itemprop="datePublished">September 2020</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.cancer.gov/nano/research/ncl" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Cancer Institute (US)</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>Potter TM, Neun BW, Dobrovolskaia MA. Detection of Mycoplasma Contamination in Nanoparticle Formulations: Version 3. 2020 Sep. In: National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]. Bethesda (MD): National Cancer Institute (US); 2005 May 1-. NCL Method STE-3.<span class="bk_cite_avail"></span> doi: 10.17917/PHFP-8573</p></div><div class="small-screen-prev"><a href="/books/n/nciprotocols/ncipr83/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/nciprotocols/ncipr72/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|